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ABSTRACT  
Objective: To determine drug resistance mutation (DRM) patterns in a large cohort of patients failing 
non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) 
regimens in programmes without routine viral load (VL) monitoring and to examine inter-subtype 
differences in DRMs.  
Design: Sequences from 787 adults/adolescents who failed an NNRTI-based first-line regimen in 13 
clinics in Uganda, Kenya, Zimbabwe, Malawi were analysed. Multivariable logistic regression was used 
to determine the association between specific DRMs and Stanford intermediate/high-level resistance 
and factors including REGA subtype, first-line ART drugs, CD4 and VL at failure.  
Results: The median first-line treatment duration was 4 years (IQR 30-43 months); 42% of participants 
had VL ≥100,000 c/ml and 63% had CD4<100cells/mm3. Viral subtype distribution was A1 (40%; 
Uganda, Kenya), C (31%; Zimbabwe, Malawi) and D (25%; Uganda, Kenya) and 
recombinant/unclassified (5%). In general, DRMs were more common in subtype-C than in subtypes-
A and/or –D (NRTI mutations K65R and Q151M; NNRTI mutations E138A, V106M, Y181C, K101E, 
H221Y). The presence of tenofovir resistance was similar between subtypes (p(adjusted)=0.32), but 
resistance to zidovudine, abacavir, etravirine or rilpivirine was more common in subtype-C than D/A 
(p(adjusted)<0.02).  
Conclusions: Non-B subtypes differ in DRMs at first-line failure that impact on residual NRTI and NNRTI 
susceptibility. In particular, higher rates of etravirine and rilpivirine resistance in subtype-C may limit 
their potential utility in salvage regimens.   
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INTRODUCTION 
Large databases of HIV drug-resistance mutations (DRMs), invaluable for individual patient clinical 
decision-making, are largely populated with data from subtype-B viruses, dominant in Europe and 
North America. The prevalence and pattern of DRMs differ between B and non-B subtypes. Studies 
comparing different non-B subtypes have typically had small numbers of participants failing first-line 
therapy, and thus limited power to detect subtype differences, given confounding associated with 
setting-specific factors, such as first-line regimens and monitoring approaches.1  
More than 15 million people receive antiretroviral therapy (ART) in sub-Saharan Africa, mostly 
delivered using the WHO public health approach that recommends using two nucleoside-reverse-
transcriptase-inhibitor (NRTI) drugs combined with a non-NRTI (NNRTI) drug for first-line treatment 
and with a protease inhibitor for second-line treatment.2 3Regular viral load (VL) monitoring is not 
widely available and treatment failure is consequently detected late, at which time there is extensive 
resistance.3 Current WHO guidelines recommend selecting the NRTI drugs for second-line therapy 
using an algorithm based on first-line NRTI drug exposure.3 An understanding of subtype differences 
in mutational patterns and residual drug susceptibility might allow more refined NRTI selection 
predictions in areas where a single subtype predominates and might also clarify the role of second-
generation NNRTIs in third-line therapy.  
We assessed resistance in a large cohort of sub-Saharan African adults/adolescents with first-line 
treatment failure to determine the impact of viral subtype on mutational patterns and corresponding 
drug susceptibility.  
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METHODS  
This study included participants failing NNRTI-based first-line therapy enrolled in the EARNEST trial, a 
large trial testing several PI-based treatment regimens for second-line therapy, and was performed at 
13 sites in 4 sub-Saharan African countries (one trial site excluded from this study, see below).4 In the 
3 to 5 years preceding this trial, these sites were delivering ART using the public health approach with 
standardised first-line ART regimens (stavudine- and nevirapine-based regimens predominating in 
earlier years, with increasing use of tenofovir- and efavirenz-based regimens subsequently). At most 
sites, first-line failure was detected using clinical monitoring, sometimes supplemented with 
intermittent CD4 monitoring. In the year prior to enrolment, some sites were performing targeted VL 
testing in suspected treatment failures, but none had implemented regular routine VL testing.  
Trial eligibility required participants to have been taking an NNRTI-based first-line regimen for >12 
months and to be currently adherent (no more than 3 ART doses missed in the month prior to 
screening). Failure of first-line ART was defined by clinical, immunological or virological criteria 
(modified from WHO 2010 guidelines and confirmed by VL>400 c/ml).4 A baseline plasma sample was 
obtained prior to switch to second-line ART, stored locally and shipped to a central repository at JCRC, 
Kampala, Uganda within 12 months of collection.  
All 37 participants recruited at one site in Zambia (3% of the total sample size) and 41 (3%) participants 
from the other 13 sites had no baseline samples stored and were excluded. Three participants not 
taking standard 2NRTI+NNRTI at failure (2 previously NNRTI-exposed, 1 ineligible4) were also excluded. 
Samples from all remaining participants randomised to protease inhibitor (PI)/NRTI (N=398) and 
PI/raltegravir (N=393) arms were selected, and 15 samples from those randomised to PI-monotherapy 
who had received only tenofovir and lamivudine/emtricitabine (with NNRTI) in their first-line regimen 
were added to increase numbers receiving the current WHO-recommended first-line regimen (total 
806 baseline samples assayed). Patient demographics, medical and treatment history (including 
antiretroviral drugs) were obtained from case records and patient self-report. VL and CD4 count were 
performed at trial screening (<6 weeks before baseline) using standard methods at local sites.  
HIV genotyping was performed using an in-house sequencing method encompassing codons 1-300 of 
reverse transcriptase  at a WHO-designated laboratory (JCRC, Kampala, Uganda).5 In brief, RNA was 
extracted using the Qiagen RNA extraction kit and reverse transcribed followed by a nested PCR. The 
cleaned PCR product was cycle sequenced using the ABI 3730xl. Sequences were edited using the 
SeqScape version 2.7 and subsequently on Recall as recommended by WHO.6 Amino acid sequences 
were compared to consensus subtype B, DRMs defined using the International AIDS Society-USA list,7 
and susceptibility predicted using the Stanford algorithm version 7.0 using the full sequence data 
available.8 Subtype was determined by the REGA algorithm version 3.0.9 Sequences of viral isolates in 
this study were submitted to GenBank.  
Statistical analysis  
Multivariable logistic regression was used to determine associations between specific DRMs and two 
main factors of interest: subtype and ART exposure at first-line failure (stavudine, tenofovir, 
zidovudine, or other NRTI for NRTI DRMs; efavirenz or nevirapine for NNRTI DRMs). As well as 
including these two factors, models adjusted for the following potential confounders: ART drug 
exposure prior to the regimen they failed on, time on first-line ART, CD4 and log10 VL at failure, and 
presence/absence of clinical failure. Exact logistic regression (continuous factors dichotomised at 
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approximate midpoints) was used where logistic regression failed due to small numbers. Similar 
approaches were used to determine associations between Stanford intermediate/high-level 
resistance to key drugs and the factors above. Participants with recombinant viruses or where no 
subtype could be determined were excluded from all models. Models did not adjust for country 
because national programmes determined the specific NRTIs used in first-line (Table 1); analyses 
assumed that any relationship between country and DRMs or susceptibility could only be realised 
through ART received and the other factors above. 
All statistical tests presented are two-sided, without adjustment for multiple comparisons. All analyses 
were done in Stata version 13.1.  
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RESULTS  
Of 806 samples taken between 12 April 2010 and 29 April 2011 and assayed, sequences were obtained 
in 787 (98%). Forty-two percent of the participants had VL≥100,000 copies/ml, and 63% had CD4<100 
cells/mm3 (Table 1). The predominant viral subtypes were A1 (40%; Uganda/Kenya), C (31%; 
Zimbabwe/Malawi) and D (25%; Uganda/Kenya) with 5% recombinants/not predicted by REGA. 
Subtypes differed significantly in duration of first-line ART and drugs prescribed: more 
stavudine/nevirapine use and longer duration on first-line ART with subtype-C and more tenofovir use 
and substitutions in first-line NRTIs (zidovudine/stavudine to tenofovir) with subtype-A/D infection.  
The overall prevalence of major DRMs by subtype is shown in Figure 1 and Supplementary Tables 1a/b. 
One or more major NRTI or NNRTI DRMs were present in 769 (98%); 3 (0.4%) had only NRTI DRMs, 21 
(3%) had only NNRTI DRMs and 745 (95%) had both. Only 18 (2%) participants had no NRTI or NNRTI 
major DRMs.  
Overall DRM prevalence (after adjustment) was broadly similar between subtypes but some significant 
differences were seen (global p<0.05). For NRTI DRMs (Figure 1, supplementary Table 1a), type-2 
thymidine analogue (TAM-2) DRMs were more common in A and C than D, K65R and Q151M were 
more common in C than both A and D (K65R more common in A than D), whereas L210W was less 
common in C than both A and D. In particular Q151M was seen in 10% of the subtype-C vs <1% of 
subtype-A/D. For NNRTI DRMs (Figure 1, supplementary Table 1b), (i) E138A, V106M, and Y181C were 
more common in C than both A and D (ii) K101E was significantly more common in C and D than A, (iii) 
H221Y was more common in A and C than D (and more common in C than D) (iv) V108I was more 
common in D than A (v) P225H was less common in C than D (the only DRM significantly less common 
in C). In particular, V106M occurred in 16% subtype-C compared with 1% A/D, whereas P225H 
occurred in 2% C vs 7% A and 11% D.  
Mutation prevalence by drug exposure is shown in Figure 2 and Supplementary Tables 2a/b. After 
adjustment, participants on zidovudine at failure were more likely to have 
T215F,T215Y,M41L,K70R,D67N,L210W,type-1 thymidine analogue (TAM-1),TAM-2 and any TAMS; 
those on tenofovir to have K65R,K70E,Y115F, and M184I; those on efavirenz to have 
K103N,P225H,Y188L and L100I, and those on nevirapine to have Y181C and G190A. 
Intermediate/high-level resistance to tenofovir and lamivudine was predicted in 57% and 95% 
respectively (Figure 3), and to etravirine and rilpivirine in 55% and 65% respectively. The proportion 
with resistance to all three NRTIs (zidovudine,abacavir,tenofovir) that might be used with 
lamivudine/emtricitabine in a second-line regimen was 50% (Table 2), and to all NNRTIs (including 
second-generation) was 55%. Much of the individual drug resistance was due to cross-resistance 
rather than previous direct exposure to that drug (Figure 4).  
After adjustment, subtype-C was associated with greater abacavir and zidovudine resistance 
compared to subtypes A and D (p<0.01), with prevalence of intermediate/high-level resistance to 
abacavir and zidovudine of 95% and 86% respectively in subtype-C compared to 84% and 72% 
respectively in subtype-A, and 81% and 70% respectively in subtype-D. There was no significant impact 
of subtype on tenofovir resistance (global p=0.32) (Table 3). Subtype-C was associated with greater 
etravirine and rilpivirine resistance compared to subtypes A and D (p<0.003) with prevalence of 
intermediate/high-level resistance to etravirine and rilpivirine of 69% and 80% respectively in subtype-
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C compared to 49% and 63% respectively in subtype-A, and 55% and 61% respectively in subtype-D 
(percentages adjusted to average over other model factors). 
Those on tenofovir at failure had less zidovudine resistance compared to those on 
zidovudine/stavudine (p<0.01) whereas those on zidovudine appeared to have more tenofovir 
resistance than those on tenofovir (p=0.06); there was no difference in abacavir resistance in those 
receiving zidovudine vs tenofovir (p=0.26). Those with first-line nevirapine exposure had more 
etravirine and rilpivirine resistance (p<0.01). After adjustment, higher VL at failure was strongly 
associated with greater tenofovir, zidovudine and abacavir resistance (p<0.01), and more weakly with 
greater etravirine resistance (p=0.04). Lower CD4 count at failure was independently associated with 
higher risk of resistance to all drugs (p<0.01).  
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DISCUSSION  
We found DRMs conferring resistance to one or more NRTI/NNRTI drugs in 98% of participants failing 
NNRTI-based first-line ART (resistance to both classes in 95%), similar to smaller studies in Malawi10, 
Nigeria11 and the A5230 study.12 Previous studies have shown that patients monitored without VL 
accumulate DRMs at a rate of 1 new TAM approximately every 15 months (low-income setting) to 4.3 
years (high-income setting), and 1 new NNRTI DRM every 1.6 years (high-income setting) with 
continued drug exposure following virological failure.13-15 The high VL/low CD4 in this cohort suggests 
that participants had protracted virological failure prior to second-line switch, consistent with the fact 
that they were managed in programmes using immunological and clinical monitoring (without regular 
VL testing) to detect treatment failure. The very high level of accumulated DRMs in this cohort is 
therefore not surprising. Conversely, although regular VL monitoring detects failure earlier and may 
allow the chance for re-suppression (one third after 3 months’ adherence support),16 resistance often 
occurs simultaneously with VL rebound so regular VL testing may not always prevent its development. 
In a research cohort taking WHO-recommended NNRTI-based first-line regimens with VL tested one 
year after starting ART, 70% of those with detectable VL had one or more DRMs, with 53% and 60% 
having 184V and NNRTI DRMs respectively.17 Similarly a large South African programme in which VL 
was tested 6-monthly found 86% of patients had at least one drug-resistance mutation at second-line 
switch, likely reflecting delays in acting upon viral load results and illustrating programmatic barriers 
to reducing resistance development.18  
This study, the largest to date of resistance in patients failing NNRTI-based first-line therapy in sub-
Saharan Africa, makes a substantial contribution to the existing literature on differences in 
mutational patterns in non-B subtypes.  In general, resistance-conferring DRMs were more common 
in subtype-C than in either or both of subtypes-A and -D. K65R was more common in subtype-C than 
A or D, supporting previous observations in subtype-C compared to subtype-AE and -B in a global 
study of patients failing stavudine-containing regimens,19 and in comparison to non-C subtypes in an 
African cohort study (although this effect was not significant after adjustment for drugs).17 
Differential codon usage has been hypothesised to underlie this difference, and could also 
contribute to other variations in resistance at failure. Q151M, a rare mutation that confers cross-
class NRTI resistance, was present in 11% of subtype-C, but negligible levels in other subtypes (not 
previously described). Subtype differences in L210W have previously been noted (higher in A than 
other subtypes in Nigeria).20  
We found more inter-subtype differences in NNRTI DRMs, with many being substantially more 
common in subtype-C than one or both other subtypes. The (almost) exclusive occurrence of V106M 
in subtype-C has been noted previously.17 This mutation confers resistance to efavirenz and nevirapine 
and was found in 31% of those in a small cohort failing first-line in South Africa.21 Another substitution 
at this position, V106I (not seen in our study) is significantly more common in subtype-G.20 
Substitutions at position 138 (found in 13% overall) confer resistance to rilpivirine and etravirine and 
are therefore particularly concerning given that these drugs may be considered for use in third-line 
therapy.7 A Kenyan study reported substitutions at this position in 14% of those failing nevirapine or 
efavirenz-based first-line, mainly subtype-A;22 and a study in Nigeria, mainly subtype G and CRF02_AG, 
found these substitution in 9%;11 our finding that these DRMs are significantly more common in 
subtype-C (18%) than in other non-B subtypes is novel (a previous study of this mutation in several 
large databases showed a difference in frequency between subtypes C and B, but not between C and 
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non-B subtypes).23 The H221Y mutation (conferring rilpivirine resistance7 and with Y181C possibly 
etravirine resistance24) has been noted in patients with non-B subtypes failing first-line nevirapine or 
efavirenz-based regimens in a predominantly subtype-G and CRF02 Nigerian cohort and subtype-C 
South African cohort.25 26 However, our study is the first to report differences between non-B subtypes 
for this mutation (more common in subtype-C). To our knowledge, the differences we found in the 
other NNRTI DRMs, K101E (rilpivirine and etravirine resistance), Y181C (resistance to all NNRTIs), 
V108I (efavirenz and nevirapine resistance) and P225H (efavirenz resistance) have not been reported 
previously.  
Arising from these DRM differences, viral subtype significantly affected the probability of resistance 
to drugs that could be used in second or third-line regimens under the public health approach. The 
much higher zidovudine resistance in subtype-C may be of practical importance given that zidovudine 
is currently recommended for use in second-line therapy after failure of a tenofovir-based regimen. 
However, participants were mainly on zidovudine/stavudine first-line and the impact of subtype on 
zidovudine susceptibility may differ for failure on tenofovir-based first-line regimens (although we 
adjusted for this). Although we found no significant difference in the proportion with tenofovir 
resistance between subtypes, only a minority of our participants were taking tenofovir at the time of 
failure. An analysis of patients failing a tenofovir-based first-line regimen in Western European cohorts 
showed a higher rate of tenofovir resistance in subtype-C compared to non-C subtypes, 27 although 
subtype does not appear to affect long-term outcomes on tenofovir-based regimens.28 The higher 
rates of etravirine and rilpivirine resistance seen in subtype-C might also be an important 
consideration in region-specific programme policy (although overall rates are high regardless of 
subtype, see below). We confirmed the effects of specific first-line NRTIs on resistance to second-line 
NRTI drugs, which form the basis for the recommendations in the WHO algorithm. We also confirmed 
the independent association between first-line nevirapine use and etravirine and rilpivirine 
resistance.29-31 Increasing use of efavirenz over nevirapine in first-line therapy may preserve second-
generation NNRTIs for potential third-line regimens, but the high rates of resistance seen even in 
participants failing on efavirenz (40% etravirine, 51% rilpivirine) suggests that these are unlikely to 
remain sufficiently active to be used in standardised regimens in the public health approach. 
Furthermore, rates of etravirine and rilpivirine resistance have been shown to increase when tested 
with deep sequencing.26 Higher VL and lower CD4 counts independently predicted resistance to all 
potential second-line NRTI drugs, as previously observed.12 The marginal associations between VL and 
etravirine and rilpivirine resistance support this arising quickly after virological failure.  
Study strengths are the large sample size, the setting within representative sub-Saharan African 
programmes following the public health approach, and well-defined first-line failure. Limitations are 
lack of data on CD4/VL monitoring during first-line ART and the few participants using the currently-
recommended tenofovir-based regimen for first-line. There is potential for residual confounding by 
setting, since viral subtypes are strongly clustered with countries, and countries used different drug 
regimens (subtype-C virus predominated in Malawi and Zimbabwe, with more stavudine and less 
tenofovir or zidovudine use at failure; NNRTI use broadly similar). Also the duration of virological 
failure on first-line ART is unknown, may be only imperfectly adjusted for by CD4 and VL at failure, and 
first-line monitoring approaches did differ between countries. Nevertheless, our large sample size 
allowed us to adjust for different regimens and patient characteristics at failure and identify some 
strong independent associations between subtype and specific DRMs. The levels of statistical 
significance seen likely indicate a true effect rather than an artefact of the multiple comparisons 
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performed. Although we did not adjust for these multiple comparisons, this does not affect the 
magnitude of observed inter-subtype differences but rather requires caution in the interpretation of 
borderline differences. 
Our study provides important information on the prevalence of DRMs in patients failing NNRTI-based 
first-line ART in these settings, allowing a more robust comparison between viral subtypes than 
hitherto possible. We found substantial differences between subtypes, with particular disadvantages 
for subtype-C, but these are likely to have limited impact on the selection of standardised second-line 
regimens for use in the public health approach. 
 
Sequences have been deposited with GenBank accession numbers KY061369 - KY062155  
11 
 
ACKNOWLEDGEMENTS  
We thank all the participants and staff from all the centres participating in the EARNEST trial. 
 
Members of the EARNEST Trial Team are:  
 
Participating Sites  
 
Uganda  
JCRC Kampala (African trial co-ordinating centre; 231) E Agweng, P Awio, G Bakeinyaga, C Isabirye, U 
Kabuga, S Kasuswa, M Katuramu, C Kityo, F Kiweewa, H Kyomugisha, E Lutalo, P Mugyenyi, D Mulima, 
H Musana, G Musitwa, V Musiime, M Ndigendawan, H Namata, J Nkalubo, P Ocitti Labejja, P Okello, P 
Olal, G Pimundu, P Segonga, F Ssali, Z Tamale, D Tumukunde, W Namala, R Byaruhanga, J Kayiwa, J 
Tukamushaba, S Abunyang, D Eram, O Denis, R Lwalanda, L Mugarura, J Namusanje, I Nankya, E 
Ndashimye, E Nabulime, D Mulima, O Senfuma.  
IDI, Kampala (216): G Bihabwa, E Buluma, P Easterbrook, A Elbireer, A Kambugu, D Kamya, M Katwere, 
R Kiggundu, C Komujuni, E Laker, E Lubwama, I Mambule, J Matovu, A Nakajubi, J Nakku, R Nalumenya, 
L Namuyimbwa, F Semitala, B Wandera, J Wanyama  
JCRC, Mbarara (97): H Mugerwa, A Lugemwa, E Ninsiima, T Ssenkindu, S Mwebe, L Atwine, H William, 
C Katemba, S Abunyang, M Acaku, P Ssebutinde, H Kitizo, J Kukundakwe, M Naluguza, K Ssegawa, 
Namayanja, F Nsibuka, P Tuhirirwe, M Fortunate  
JCRC Fort Portal (66): J Acen, J Achidri, A Amone, M. Chamai, J Ditai, M Kemigisa, M Kiconco, C Matama, 
D Mbanza, F Nambaziira, M Owor Odoi, A Rweyora, G. Tumwebaze  
San Raphael of St Francis Hospital, Nsambya (48): H Kalanzi, J Katabaazi, A Kiyingi, M Mbidde, M. 
Mugenyi, R Mwebaze, P Okong, I Senoga  
JCRC Mbale (47): M Abwola, D Baliruno, J Bwomezi, A Kasede, M Mudoola, R Namisi, F Ssennono, S 
Tuhirwe  
JCRC Gulu (43): G Abongomera, G Amone, J Abach, I Aciro, B Arach, P Kidega, J Omongin, E Ocung, W 
Odong, A Philliam  
JCRC Kabale (33): H Alima, B Ahimbisibwe, E Atuhaire, F Atukunda, G Bekusike, A Bulegyeya, D. 
Kahatano, S Kamukama, J Kyoshabire, A Nassali, A Mbonye, T M Naturinda, Ndukukire, A 
Nshabohurira, H. Ntawiha, A Rogers, M Tibyasa;  
JCRC Kakira (31): S. Kiirya, D. Atwongyeire, A. Nankya, C. Draleku, D. Nakiboneka, D. Odoch, L. Lakidi, 
R. Ruganda, R. Abiriga, M. Mulindwa, F. Balmoi, S. Kafuma, E. Moriku  
Zimbabwe 
University of Zimbabwe Clinical Research Centre, Harare (265): J Hakim, A Reid, E Chidziva, G Musoro, 
C Warambwa, G Tinago, S Mutsai, M 
Phiri, S Mudzingwa, T Bafana, V Masore, C Moyo, R Nhema, S Chitongo  
Malawi  
Department of Medicine, University of Malawi College of Medicine and the Malawi-Liverpool-
Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine (92): Robert 
Heyderman, Lucky Kabanga, Symon Kaunda, Aubrey Kudzala, Linly Lifa, Jane Mallewa, Mike Moore, 
Chrissie Mtali, George Musowa, Grace Mwimaniwa, Rosemary Sikwese, Joep van Oosterhout, Milton 
Ziwoya  
12 
 
Mzuzu Central Hospital, Mzuzu (19): H Chimbaka. B Chitete, S Kamanga, T Kayinga E Makwakwa, R 
Mbiya, M Mlenga, T Mphande, C Mtika, G Mushani, O Ndhlovu, M Ngonga, I Nkhana, R Nyirenda  
Kenya 
Moi Teaching and Referral Hospital (52): P Cheruiyot, C Kwobah, W Lokitala Ekiru, M Mokaya, A 
Mudogo, A Nzioka, A Siika, M Tanui, S Wachira, K Wools-Kaloustian  
Zambia  
University Teaching Hospital (37): P Alipalli, E Chikatula, J Kipaila, I Kunda, S Lakhi, J Malama, W 
Mufwambi, L Mulenga, P Mwaba, E Mwamba, A Mweemba, M Namfukwe  
The Aids Support Organisation (TASO), Uganda: E Kerukadho, B Ngwatu, J Birungi 
MRC Clinical Trials Unit: N Paton, J Boles, A Burke, L Castle, S Ghuman, L Kendall, A Hoppe, S Tebbs, 
M Thomason, J Thompson, S Walker, J Whittle, H Wilkes, N Young 
Monitors: C Kapuya, F Kyomuhendo, D Kyakundi, N Mkandawire, S Mulambo, S Senyonjo 
Clinical Expert Review Committee: B Angus, A Arenas-Pinto, A Palfreeman, F Post, D Ishola  
European Collaborators:  
J Arribas (Hospital La Paz, Madrid, Spain), R Colebunders (Institute of Tropical Medicine, Antwerp, 
Belgium), M Floridia (ISS, Italy), M Giuliano (ISS, Italy), P Mallon (University College Dublin, Ireland), P 
Walsh (University College Dublin, Ireland), M De Rosa (CINECA, Italy), E Rinaldi (CINECA, Italy) 
Trial Steering Committee: I Weller (Chair), C Gilks, J Hakim, A Kangewende, S Lakhi, E Luyirika, F Miiro, 
P Mwamba, P Mugyenyi, S Ojoo, N Paton, S Phiri, J van Oosterhout, A Siika, S Walker, A Wapakabulo,  
Data Monitoring Committee: T Peto (Chair), N French, J Matenga 
Pharmaceutical companies: G Cloherty, J van Wyk, M Norton, S Lehrman, P Lamba, K Malik, J Rooney, 
W Snowden, J Villacian 
 
Funding and in-kind support:  
The EARNEST trial was funded by the European and Developing Countries Clinical Trials Partnership 
(EDCTP, Grant Code: IP.2007.33011.003) with contributions from the Medical Research Council, UK; 
Institito de Salud Carlos III, Spain (Grant A107/90015); Irish Aid, Ireland; Swedish International 
Development Cooperation Agency (SIDA), Sweden; Instituto Superiore di Sanita (ISS), Italy; The World 
Health Organisation; and Merck, USA. Substantive in-kind contributions were made by the Medical 
Research Council Clinical Trials Unit, UK, CINECA, Bologna, Italy, Janssen Diagnostics, Beerse, Belgium; 
GSK/ViiV Healthcare Ltd., UK; Abbott Laboratories, USA. Trial medication was donated by AbbVie, 
Merck, Pfizer, GSK and Gilead. The Malawi-Liverpool-Wellcome Trust Clinical Research Programme, 
University of Malawi College of Medicine receives core funding from the Wellcome Trust UK.  
  
13 
 
REFERENCES 
1. Bhargava M, Cajas JM, Wainberg MA, Klein MB, Pant Pai N. Do HIV-1 non-B subtypes 
differentially impact resistance mutations and clinical disease progression in treated populations? 
Evidence from a systematic review. Journal of the International AIDS Society 2014; 17: 18944. 
2. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral 
treatment against HIV in resource-limited settings. Lancet 2006; 368(9534): 505-10. 
3. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection: recommendations for a public health approach. . Geneva: 
World Health Organisation 2016. 
4. Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV 
therapy in Africa. N Engl J Med 2014; 371(3): 234-47. 
5. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated 
Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum 
Retroviruses 2004; 20(4): 355-64. 
6. Woods CK, Brumme CJ, Liu TF, et al. Automating HIV drug resistance genotyping with RECall, 
a freely accessible sequence analysis tool. Journal of clinical microbiology 2012; 50(6): 1936-42. 
7. Wensing AM, Calvez V, Gunthard HF, et al. 2014 update of the drug resistance mutations in 
HIV-1. Top Antivir Med 2014; 22(3): 642-50. 
8. Stanford HIV Drug Resistance Database. 2014. http://hivdb.stanford.edu/. 
9. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of 
HIV-1 and other microbial sequences. Bioinformatics 2005; 21(19): 3797-800. 
10. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify 
antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among 
Malawians failing first-line antiretroviral therapy. AIDS 2009; 23(9): 1127-34. 
11. Etiebet MA, Shepherd J, Nowak RG, et al. Tenofovir-based regimens associated with less 
drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. AIDS 2013; 27(4): 
553-61. 
12. Wallis CL, Aga E, Ribaudo H, et al. Drug susceptibility and resistance mutations after first-line 
failure in resource limited settings. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America 2014; 59(5): 706-15. 
13. Sigaloff KC, Ramatsebe T, Viana R, de Wit TF, Wallis CL, Stevens WS. Accumulation of HIV 
drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS 
Res Hum Retroviruses 2012; 28(2): 171-5. 
14. Cozzi-Lepri A, Paredes, Phillips AN, et al. The rate of accumulation of nonnucleoside reverse 
transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen 
containing an NNRTI*. HIV medicine 2012; 13(1): 62-72. 
15. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. Rate of accumulation of thymidine 
analogue mutations in patients continuing to receive virologically failing regimens containing 
zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited 
settings. J Infect Dis 2009; 200(5): 687-97. 
16. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in 
human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South 
Africa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of 
America 2009; 49(12): 1928-35. 
17. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line 
antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line 
ART strategies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of 
America 2012; 54(11): 1660-9. 
18. Manasa J, Lessells RJ, Skingsley A, et al. High-levels of acquired drug resistance in adult 
patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, 
South Africa. PLoS One 2013; 8(8): e72152. 
14 
 
19. Tang MW, Rhee SY, Bertagnolio S, et al. Nucleoside reverse transcriptase inhibitor resistance 
mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic 
implications for countries phasing out stavudine. J Infect Dis 2013; 207 Suppl 2: S70-7. 
20. Chaplin B, Eisen G, Idoko J, et al. Impact of HIV type 1 subtype on drug resistance mutations 
in Nigerian patients failing first-line therapy. AIDS Res Hum Retroviruses 2011; 27(1): 71-80. 
21. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance 
genotypes in treatment-naive patients and after first virological failure in a large community 
antiretroviral therapy programme. Antiviral therapy 2009; 14(4): 523-31. 
22. Crawford KW, Njeru D, Maswai J, et al. Occurrence of etravirine/rilpivirine-specific resistance 
mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing 
antiretroviral therapy. Aids 2014; 28(3): 442-5. 
23. Sluis-Cremer N, Jordan MR, Huber K, et al. E138A in HIV-1 reverse transcriptase is more 
common in subtype C than B: implications for rilpivirine use in resource-limited settings. Antiviral 
research 2014; 107: 31-4. 
24. Maiga AI, Descamps D, Morand-Joubert L, et al. Resistance-associated mutations to 
etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. Antimicrob 
Agents Chemother 2010; 54(2): 728-33. 
25. Taiwo B, Chaplin B, Penugonda S, et al. Suboptimal etravirine activity is common during 
failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B 
subtype HIV-1. Curr HIV Res 2010; 8(3): 194-8. 
26. Casadella M, Noguera-Julian M, Sunpath H, et al. Treatment options after virological failure 
of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing. AIDS 2016; 
30(7): 1137-40. 
27. TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO 
recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. 
Lancet Infect Dis 2016; 16: 565-75. 
28. White E, Smit E, Churchill D, et al. No Evidence That HIV-1 Subtype C Infection Compromises 
the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom. J Infect Dis 
2016. 
29. Anta L, Llibre JM, Poveda E, et al. Rilpivirine resistance mutations in HIV patients failing non-
nucleoside reverse transcriptase inhibitor-based therapies. AIDS 2013; 27(1): 81-5. 
30. van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W. Antiretroviral resistance 
patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the 
Western Cape, South Africa. J Med Virol 2011; 83(10): 1764-9. 
31. Kiertiburanakul S, Wiboonchutikul S, Sukasem C, Chantratita W, Sungkanuparph S. Using of 
nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected 
patients who experienced virologic failure in a resource-limited setting. J Clin Virol 2010; 47(4): 330-
4. 
  
15 
 
Table 1: Characteristics of study population at first line failure  
Characteristic at first 
line failure 
Overall 
N=787 
 
n (%) 
Subtype-A 
N=311  
40% 
n (%) 
Subtype-C 
N=244  
31% 
n (%) 
Subtype-D 
N=194  
25% 
n (%) 
Recombinant* 
N=38  
5% 
n (%) 
P value 
Country n(%)       
 Kenya 33 (4%) 20 (6%) 3 (1%) 7 (4%) 3 (8%) 
<0.001 
 Malawi 69 (9%) 0 68 (28%) 0 1 (3%) 
 Uganda 516 (66%) 289 (93%) 12(5%) 186 (96%) 29 (76%) 
 Zimbabwe 169 (21%) 2 (1%) 161 (66%) 1 (1%) 5 (13%) 
Sex n(%)       
 Female 485 (62%) 193 (62%) 141 (58%) 126 (65%) 25 (66%) 
0.44 
 Male 302 (38%) 118 (38%) 103 (42%) 70 (36%) 13 (34%) 
Age median(IQR) 37 (30-43) 36 (30-42) 39 (33-45) 35 (30-42) 34 (29-43) <0.001 
Years on first-line therapy 
median (IQR) 
4.0 (2.8-5.4) 3.8 (2.7-5.3) 4.3 (3.1-5.5) 3.9 (2.8-5.4) 3.8 (2.8-5.2) 
0.02 
2 or more CD4s on first-
line therapy** 
549 (70%) 284 (91%) 71 (29%) 163 (84%) 31 (82%) 
<0.001 
1 or more VLs on first-line 
therapy** 
160 (20%) 75 (24%) 26 (11%) 51 (26%) 8 (21%) 
<0.001 
Drug exposure in first line 
therapy n(%) 
     
 
 Number of regimens        
 1 398 (51%) 151 (49%) 141 (58%) 88 (45%) 18 (47%) 
0.09  2 324 (41%) 129 (41%) 89 (36%) 91 (47%) 15 (39%) 
 3+ 65 (8%) 31 (10%) 14 (6%) 15 (8%) 5 (13%) 
 NNRTI       
 Number exposed to        
 1 660 (84%) 270 (87%) 194 (80%) 166 (86%) 30 (79%) 
0.09 
 2 127 (16%) 41 (13%) 50 (20%) 28 (14%) 8 (21%) 
 NNRTI at failure       
 Efavirenz 193 (25%) 84 (27%) 45 (18%) 54 (28%) 10 (26%) 0.05 
  Nevirapine 594 (75%) 227 (73%) 199 (82%) 140 (72%) 28 (74%) 
 NRTI       
 Number exposed to        
 2 467 (59%) 173 (56%) 174 (70%) 100 (52%) 24 (63%) 
0.001  3 293 (37%) 125 (40%) 69 (28%) 86 (44%) 13 (34%) 
 4/5 27 (3%) 13 (4%) 5 (2%) 8 (4%) 1 (3%) 
 NRTI at failure       
 Tenofovir 96(12%) 56 (18%) 3 (1%) 31 (16%) 6 (16%) 
<0.001 
 
 Stavudine 200 (25%) 21 (7%) 162 (66%) 8 (4%) 9 (24%) 
 Zidovudine 486 (62%) 233 (75%) 76 (31%) 154 (79%) 23 (61%) 
 None of the 
above † 
5 (1%) 1 (0%) 3 (1%) 1 (1%) 0 
CD4 (cells/mm3)        
 median (IQR) 67 (27-136) 69 (26-151) 66 (25-116) 71 (30-140) 54 (25-129) 0.47 
 <100 n(%) 495 (63%) 191 (61%) 161 (66%) 119 (61%) 24 (63%)  
16 
 
Viral load (copies/ml)        
 median (IQR) 74,500 
(25,400-
194,130) 
74,100 
(23,906- 
183,935) 
77,679 
(27,591-
250,864) 
59,760 
(24,135 -
163,417) 
148,500 
(43,542-
240,725) 
0.33 
 ≥100,000 n(%) 334 (42%) 131 (42%) 109 (45%) 72 (37%) 22 (58%)  
* called by REGA as a recombinant or not called by REGA. 
** excluding values at ART initiation and within the 90 days preceding switch to second-line (since some 
additional testing was done as part of trial recruitment initiatives) 
† 1 didanosine, 4 abacavir  
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Table 2: Resistance to potential future NRTI and NNRTI drug options 
 
Drug 
Intermediate/ high 
resistance (N=787) 
n(%) 
High resistance 
(N=787) 
n(%) 
NRTI   
ABC TDF ZDV 392 (50%) 191 (24%) 
ABC ZDV (not TDF) 168 (21%) 177 (22%) 
ABC TDF (not ZDV) 54 (7%) 51 (6%) 
ABC (not TDF ZDV) 32 (4%) 18 (2%) 
ZDV (not TDF ABC) 0 111 (14%) 
TDF (not ZDV ABC) 0 2 
None of ABC TDF ZDV 141 (18%) 237 (30%) 
NNRTI    
EFV NVP ETR RPV 432 (55%) 83 (11%) 
EFV NVP RPV (not ETR) 79 (10%) 98 (12%) 
NVP ETR RPV (not RPV) 0 19 (2%) 
EFV NVP (not ETR RPV) 252 (32%) 373 (47%) 
NVP RPV (not EFV ETR) 2 6 (1%) 
NVP (not EFV ETR RPV) 1 184 (23%) 
None of EFV NVP ETR RPV 21 (3%) 24 (3%) 
 
ABC=abacavir, TDF=tenofovir, ZDV=zidovudine,  
EFV=efavirenz, NPV=nevirapine, ETR=etravirine, RPV=rilpivirine 
18 
 
Table 3: Factors predicting intermediate/ high level resistance to drugs for potential use in a second-line regimen  
 Abacavir resistance Tenofovir resistance Zidovudine resistance Etravirine resistance Rilpivirine resistance 
 OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
NRTI at failure  <0.001  <0.001  <0.001     
Tenofovir vs Stavudine 10.77 (3.51, 33.05) <0.001 1.76 (0.82, 3.78) 0.15 0.31 (0.13, 0.75) 0.009     
Zidovudine vs Stavudine 6.24 (3.00, 13.01) <0.001 3.13 (1.76, 5.59) <0.001 6.27 (3.24, 12.13) <0.001     
Zidovudine vs Tenofovir 0.58 (0.23, 1.48) 0.26 1.78 (0.98, 3.24) 0.06 20.21 (9.98, 40.96) <0.001     
NNRTI at failure           
Nevirapine vs Efavirenz       3.39 (2.11, 5.47) <0.001 2.88 (1.84, 4.50) <0.001 
NRTIs prior to failure           
None (failed on initial 
NRTIs) 
1 
0.04 
1 
0.14 
1 
<0.001 
    
Stavudine only 1.78 (0.99, 3.22) 1.31 (0.86, 2.01) 1.51 (0.90, 2.55)     
Zidovudine only 7.82 (0.94, 65.01) 2.58 (0.93, 7.14) 3.80 (1.34, 10.80)     
Stavudine and 
Zidovudine 
4.21 (0.40, 44.19) 2.11 (0.69, 6.51) 8.59 (2.70, 27.28)     
NNRTIs prior to failure (vs 
failed on first NNRTI) 
          
Efavirenz        0.51 (0.26, 1.00) 
0.004 
0.39 (0.20, 0.76) 
0.005 
Nevirapine        2.47 (1.28, 4.76) 1.76 (0.92, 3.37) 
Subtype  0.002  0.32  0.02  <0.001  <0.001 
C vs A 3.31 (1.59, 6.88) 0.001 1.31 (0.78, 2.20) 0.30 2.34 (1.24, 4.42) 0.009 2.37 (1.61, 3.47) <0.001 2.28 (1.51, 3.46) <0.001 
C vs D 4.08 (1.85, 9.03) 0.001 1.53 (0.88, 2.67) 0.13 2.54 (1.28, 5.05) 0.008 1.88 (1.23, 2.87) 0.003 2.45 (1.56, 3.85) <0.001 
D vs A 0.81 (0.48, 1.36) 0.43 0.85 (0.57, 1.27) 0.44 0.92 (0.58, 1.46) 0.73 1.26 (0.87, 1.83) 0.23 0.93 (0.64, 1.36) 0.72 
Log10 viral load at failure 1.58 (1.15, 2.16) 0.003 1.95 (1.50, 2.53) <0.001 1.53 (1.15, 2.02) 0.003 1.29 (1.01, 1.64) 0.04 1.21 (0.94, 1.56) 0.15 
CD4 at failure (per 100 cell 
increase) 
0.59 (0.48, 0.72) <0.001 0.48 (0.39, 0.59) <0.001 0.66 (0.55, 0.80) <0.001 0.79 (0.67, 0.93) 0.004 0.75 (0.64, 0.89) 0.001 
Clinical failure 0.79 (0.43, 1.46) 0.45 0.99 (0.61, 1.61) 0.96 0.75 (0.44, 1.29) 0.31 1.24 (0.76, 2.00) 0.39 1.32 (0.78, 2.25) 0.30 
Years on ART 1.13 (0.99, 1.28) 0.07 1.03 (0.95, 1.13) 0.47 1.19 (1.06, 1.33) 0.003 0.99 (0.92, 1.07) 0.85 0.99 (0.91, 1.07) 0.74 
Fit statistic 
Area under the ROC curve 76% (71%, 80%)  75% (71%, 78%)  78% (74%, 82%)  69% (65%, 73%)  70% (66%, 74%)  
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Figure 1: Prevalence of major IAS-USA drug resistance mutations by HIV-1 subtype  
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Figure 2 Prevalence of major IAS-USA drug resistance mutations by drug exposure at first line failure  
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Figure 3: Overall resistance to NRTI and NNRTI drugs  
 
 
Exposure 99% 5% 1% 13% 68% 0% 62%  30% 86% 0% 0% 
High 
Resistance 
93% 93% 56% 31% 61% 54% 63%  70% 97% 13% 26% 
Intermediate/ 
high 
Resistance 
95% 95% 82% 57% 71% 75% 77%  97% 97% 55% 65% 
 
  
0
20
40
60
80
100
P
e
rc
e
n
ta
g
e
NRTI NNRTI
3TC FTC ABC TDF ZDV DDI D4T EFV NVP ETR RPV
Susceptible Potential low Low Intermediate High
0
20
40
60
80
100
P
e
rc
e
n
ta
g
e
NRTI NNRTI
3TC FTC ABC TDF ZDV DDI D4T EFV NVP ETR RPV
Susceptible Potential low Low Intermediate High
Percentage with any mutation 
22 
 
Figure 4a: Intermediate/high level resistance according to exposure or cross-resistance 
 
 
Figure 4b: High level resistance according to exposure or cross-resistance 
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